If you experience nausea during this period, it is usually mild and manageable
Pills are also easier to manufacture than injectable pens, which could help avoid the frustrating supply problems that slowed earlier GLP-1 launches
The Endocrine Society's 2023 obesity pharmacotherapy guideline states: "When a patient does not achieve adequate weight loss on a maximally tolerated dose of a GLP-1 receptor agonist, switching to an agent with a broader receptor profile is a reasonable escalation strategy, provided the patient is counseled on the investigational status of newer agents" [5]
step therapy required BCBS of Illinois Covered with PA BMI criteria + documented diet/exercise failure BCBS of Michigan Not covered (fully insured) Removed all GLP-1 weight loss drugs from commercial plans Jan 2025 BCBS of Florida (Florida Blue) Covered with PA BMI 30
Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S
THC, cocaine, opioids, amphetamines, PCP, with expanded panels adding benzodiazepines, barbiturates, and others
